Graves Disease Market: Current Analysis and Forecast (2024-2032)
Emphasis on Treatment Type (Anti-Thyroid Medications, Beta-Blockers, Radioactive Iodine Therapy, Surgery (Thyroidectomy), Adjunctive Therapies, and Emerging Treatments); End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Homecare Settings); and Region/Country
Global Graves Disease Market Size & Forecast
The Global Graves Disease Market was valued at ~USD 350 million in 2023 and is expected to grow at a strong CAGR of around ~5% during the forecast period (2024-2032) owing to increased awareness about thyroid disorders and their symptoms is driving more people to seek diagnosis and treatment.
Global Graves Disease Market Analysis
The market size of graves disease across the globe is expansive and expanding because of several factors. It is characterized by the rising incidence of auto-immune diseases, the enhancement of diagnostic capabilities, advancement in awareness of thyroid diseases, and innovation in treatments. Further, key drivers of Graves’ disease diagnosis market growth include the growing global populace with poor health, existing genes affecting the occurrence of Graves’ disease, and environmental dangers. Further, measures for upgrading the healthcare infrastructure along with educating patients enlarging support programs, and increasing the market penetration, particularly in developing economies are steering the worldwide graves disease market at a faster pace.
For instance, In March 2021, BridgeBio Pharma announced positive outcomes from the second stage trial of its new drug Encaleret. As a part of hypoparathyroidism treatments, the drug has shown effectiveness among patients with autosomal dominant hypocalcemia type 1.
Global Graves Disease Market Trends
This section discusses the key market trends that are influencing the various segments of the global graves disease market, as identified by our team of research experts.
Beta-Blockers Segment Transforming Industry
The beta-blockers segment is the key factor that shapes the graves disease market by providing relief in symptoms like rapid heartbeat, tremors, and anxiety associated with hyperthyroidism. Beta-blockers act on the adrenergic receptors to counteract adrenaline’s effects on the heart; these actions help to minimize such symptoms and increase patient satisfaction. Similarly, they can also be utilized as an additive treatment regime along with antithyroid medications or radioactive iodine treatment for the comprehensive treatment of Graves’ disease. Beta-blockers are the drugs that are chosen for the therapy of Graves’ disease because of their efficacy, reasonable cost, and easy accessibility, thus stimulating the development of this market.
Asia-Pacific is Expected to Grow at a Significant CAGR During Forecast Period
Graves’ disease landscape in the Asia-Pacific region indicates that there is significant future expansion to occur due to several factors. The world’s largest population group and the ever-growing aging group of population especially in Asian countries such as China and Japan are experiencing an increasingly increased rate of auto immune diseases such as graves’ disease. Further, the high prevalence of thyroid disorders across the global population and rising healthcare services adoptions are leading to enhanced identification and treatment solutions, driving growth in the market. Also, increased incidences of thyroid cancer through new innovative therapies such as anti-thyroid medications and radioactive iodine therapy in Asia-Pacific due to research and development of pharmaceutical companies are escalating the market in the Asia-Pacific region.
Global Graves Disease Industry Overview
The Global Graves Disease Market is competitive, with several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new type launches, geographical expansions, and mergers and acquisitions. Some of the major players operating in the market are Merck & Co., Inc.; Abbott; Pfizer Inc.; GSK plc.; AbbVie Inc.; RLC Labs; Mylan N.V.; F. Hoffmann-La Roche Ltd; Medtronic; Ascendis Pharma
Global Graves Disease Market Report Coverage
Reasons to buy this report:
- The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
- The report presents a quick review of overall industry performance at one glance.
- The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, type portfolios, expansion strategies, and recent developments.
- Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
- The study comprehensively covers the market across different segments.
- Deep dive regional level analysis of the industry.
Customization Options:
The Global Graves Disease Market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
Table of Contents
Research Methodology for the Global Graves Disease Market Analysis (2024-2032)
Analyzing the historical market, estimating the current market, and forecasting the future market of the Graves disease market were the three major steps undertaken to create and analyze the adoption of global graves disease in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global graves disease market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:
Analysis of Historical Market Size
Step 1: In-Depth Study of Secondary Sources:
A detailed secondary study was conducted to obtain the historical market size of the global graves disease market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the global graves disease market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as treatment type, end-user, and regions. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the global graves disease market. Further, we conducted factor analysis using dependent and independent variables such as treatment type, end-user, and regions of the global graves disease market. A thorough analysis was conducted of demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and type launches in the global graves disease market sector across the globe.
Current Market Size Estimate & Forecast
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global graves disease market, and market shares of the segments. All the required percentage shares split and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to several factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2032 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
- The industry’s market size, in terms of revenue (USD) and the adoption rate of the Global Graves Disease market across the major markets domestically
- All percentage shares, splits, and breakdowns of market segments and sub-segments
- Key players in the Global Graves Disease market in terms of types offered. Also, the growth strategies adopted by these players to compete in the fast-growing market
Market Size and Share Validation
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Split of Primary Participants in Different Regions
Market Engineering
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global graves disease market. Data was split into several segments and sub-segments after studying various parameters and trends in the treatment type, end-user, and regions in the Global Graves Disease market.
The main objective of the Global Graves Disease Market Study
The current & future market trends of the Global Graves Disease market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
- Analyze the current and forecast market size of the global graves disease market in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments.
- Segments in the study include areas of the treatment type, end-user, and regions.
- Define and analyze the regulatory framework for the industry.
- Analyze the value chain involved with the presence of various intermediaries, along with analyzing customer and competitor behaviors of the industry.
- Analyze the current and forecast market size of the global graves disease market for the major regions.
- Major countries of regions studied in the report include Asia Pacific, Europe, North America, and the Rest of the World
- Company profiles of the global graves disease market and the growth strategies adopted by the market players to sustain in the fast-growing market.
- Deep dive regional level analysis of the industry
Frequently Asked Questions FAQs
Q1: What is the global graves disease market's current market size and growth potential?
Q2: What are the driving factors for the growth of the global graves disease market?
Q3: Which segment has the largest share of the global graves disease market by treatment type category?
Q4: What are the emerging technologies and trends in the global graves disease market?
Q5: Which region will dominate the global graves disease market?
Related Reports
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
